Skip to main content
JA Clinical Reports logoLink to JA Clinical Reports
letter
. 2020 Nov 21;6:93. doi: 10.1186/s40981-020-00399-4

Hypotension caused by oral administration of 5-aminolevulinic acid persists after surgery in patients undergoing transurethral resection of bladder tumor under spinal anesthesia

Masami Sato 1,, Tsutomu Yanagisawa 1, Sonoko Minamino 1, Toshiyuki Arai 1
PMCID: PMC7680493  PMID: 33219885

To the Editor,

5-Aminolevulinic acid (ALA) is utilized for photodynamic diagnosis to detect superficial bladder cancer and its adverse effect is hypotension [15]. Compared to general anesthesia, spinal anesthesia is not indicated as an increased risk factor for 5-ALA-induced hypotension from anesthesia induction to the start of surgery in patients undergoing transurethral resection of bladder tumor (TUR-BT) with 5-ALA [2, 3]. However, no studies exist that have investigated the precise perioperative hypotensive effects by 5-ALA under spinal anesthesia. This retrospective study assessed the hypotensive effect of 5-ALA on hemodynamic change of spinal anesthesia in patients undergoing TUR-BT not only during surgery but also after the ward admission.

The medical records of 129 patients who underwent TUR-BT under spinal anesthesia using 0.5% hyperbaric bupivacaine in Kyoto City Hospital between January 2018 and March 2019 were divided into two groups, based on whether 5-ALA was used (ALA group, n = 66) or not used (control group, n = 63). The ALA group received 5-ALA (20 mg/kg) orally 3 h before the start of surgery. The change in noninvasive blood pressure (BP) on the day of surgery and the dosage of vasopressors used during spinal anesthesia were analyzed.

No significant difference existed between the two groups in the patients’ preoperative characteristics. Intravenous fluid volume during anesthesia was significantly higher in the ALA group than in the control group (Table 1). Systolic and diastolic BP were significantly lower in the ALA group than in the control group from spinal anesthesia until 2 h after the ward admission. In the ALA group, systolic and diastolic BP significantly remained decreased from spinal anesthesia until 2 h after the ward admission (Fig. 1). The total dosage of ephedrine and phenylephrine were higher in the ALA group than in the control group (Table 1).

Table 1.

The patients’ preoperative characteristics, anesthesia profiles and the drugs administered during anesthesia

Control group (n = 63) ALA group (n = 66) P value
Age (years) 71 ± 11 74 ± 10 0.27
Height (cm) 162 ± 15 161 ± 14 0.58
Weight (kg) 65 ± 17 65 ± 18 0.97
Sex (male/female) 59 (94%)/4 (6%) 55 (83%)/11 (17%) 0.07
Regular use of antihypertensive drug 24 (38%) 23 (35%) 0.70
Regular use of renin-angiotensin system inhibitor 14 (22%) 11 (17%) 0.42
Duration of surgery (minutes) 43 ± 25 44 ± 20 0.84
Duration of anesthesia (minutes) 75 ± 28 80 ± 22 0.25
Dose of 0.5% hyperbaric bupivacaine of spinal anesthesia (mL) 3.1 ± 0.3 3.0 ± 0.3 0.20
Sensory block level just before surgerya T8 (T2–T11) T6 (T2–L1) 0.26
Sensory block level at the end of surgerya T6 (T2–T12) T5 (T2–T12) 0.49
Intravenous fluid volume during anesthesia (mL) 570 ± 191 758 ± 284 < 0.001
Use of vasopressorsb 10 (16%) 47 (71%) < 0.001
Use of ephedrine 8 (13%) 37 (56%) < 0.001
Total dose of ephedrine (mg) 1.0 ± 3.0 6.9 ± 9.0 < 0.001
Use of phenylephrine 6 (10%) 30 (45%) < 0.001
Total dose of phenylephrine (mg) 0.013 ± 0.042 0.21 ± 0.34 < 0.001

Values are presented as mean ± standard deviation or number (%)

aMedian (maximum-minimum)

bEphedrine or phenylephrine or both were used

ALA aminolevulinic acid

Fig. 1.

Fig. 1

Time courses of systolic blood pressure and diastolic blood pressure. Values are presented as mean ± standard deviation. *P < 0.05, post-operating room admission versus before 5-ALA p.o./morning. #P < 0.05, the ALA group versus the control group. ALA aminolevulinic acid, BP blood pressure, p.o. per os

Additive hypotensive effect induced by spinal anesthesia and 5-ALA was prominent after spinal anesthesia induction not only during surgery but also for 2 h after the ward admission, as shown by the BP changes in our ALA group. Since the duration of the hypotensive effect by 5-ALA is longer than that of hyperbaric bupivacaine of spinal anesthesia, the systolic BP in the ALA group did not return to the baseline level even 2 h after the ward admission, unlike in the control group. We cannot easily state that spinal anesthesia using hyperbaric bupivacaine is a safe technique from our result, when considering the postoperative period. Our reflection point is that hypotension may be encouraged by hypovolemia in the ALA group, because all patients did not have intravenous fluids after 5-ALA administration before spinal anesthesia. Other risk factors that increase the incidence of 5-ALA-induced hypotension have been reported to be the regular use of antihypertensive drugs, particularly renin-angiotensin system inhibitor drugs [2, 4] and a history of ALA-induced hypotension [5].

In conclusion, orally administered 5-ALA before TUR-BT under spinal anesthesia induced significant hypotension after spinal anesthesia induction until 2 h after surgery and an increased need for vasopressors and intravenous volume. Anesthesiologists should have a strategy for safe anesthetic management against long-lasting hypotension by 5-ALA.

Acknowledgements

Not applicable

Abbreviations

ALA

Aminolevulinic acid

TUR-BT

Transurethral resection of bladder tumor

BP

Blood pressure

Authors’ contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by MS, TY, and SM. The first draft of the manuscript was written by MS and supervised by TA. All authors read and approved the final manuscript.

Funding

None

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the institutional ethics committee of Kyoto City Hospital (approval no. 514) and the requirement for informed consent was waived according to the retrospective nature of the study.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Masami Sato, Email: masami@kb3.so-net.ne.jp.

Tsutomu Yanagisawa, Email: sppc21hv06@yahoo.co.jp.

Sonoko Minamino, Email: higasono@gmail.com.

Toshiyuki Arai, Email: arai@kuhp.kyoto-u.ac.jp.

References

  • 1.Herman MA, Webber J, Fromm D, Kessel D. Hemodynamic effects of 5-aminolevulinic acid in humans. J Photochem Photobiol B. 1998;43:61–65. doi: 10.1016/S1011-1344(98)00086-4. [DOI] [PubMed] [Google Scholar]
  • 2.Nohara T, Kato Y, Nakano T, Nakagawa T, Iwamoto H, Yaegashi H, et al. Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. Int J Urol. 2019;26:1064–1068. doi: 10.1111/iju.14099. [DOI] [PubMed] [Google Scholar]
  • 3.Yatabe T, Karashima T, Kume M, Kawanishi Y, Fukuhara H, Ueba T, et al. Identification of risk factors for post-induction hypotension in patients receiving 5-aminolevulinic acid: a single-center retrospective study. JA Clin Rep. 2020;6:35. doi: 10.1186/s40981-020-00340-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chung IW, Eljamel S. Risk factors for developing oral 5-aminolevulinic acid-induced side effects in patients undergoing fluorescence guided resection. Photodiagn Photodyn Ther. 2013;10:362–367. doi: 10.1016/j.pdpdt.2013.03.007. [DOI] [PubMed] [Google Scholar]
  • 5.Bondad J, Aboumarzouk OM, Moseley H, Kata SG. Oral 5-aminolevulinic acid induced photodynamic diagnostic ureterorenoscopy - does the blood pressure require monitoring? Photodiagn Photodyn Ther. 2013;10:39–41. doi: 10.1016/j.pdpdt.2012.06.004. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.


Articles from JA Clinical Reports are provided here courtesy of Springer

RESOURCES